

# SFPT 2018

TOULOUSE | Faculté de Médecine | 12 - 14 juin 2018

## PROGRAMME

22<sup>e</sup> Congrès de la Société Française  
de Pharmacologie et de Thérapeutique



Société Française de  
Pharmacologie et de Thérapeutique

# SFPT 2018

TOULOUSE | Faculté de Médecine | 12 - 14 juin 2018

4	SOCIÉTÉS ET COMITÉS
5	MOT DE BIENVENUE
6/7	PROGRAMME EN UN COUP D'ŒIL
8/37	PROGRAMME SCIENTIFIQUE
8/19	Mardi 12 Juin
20/28	Mercredi 13 Juin
29/32	Jeudi 14 Juin
32/37	LISTE DES POSTERS
38/39	INFORMATIONS PRATIQUES
40/41	NOTES
42	REMERCIEMENTS



# SOCIÉTÉS & COMITÉS

## CONSEIL D'ADMINISTRATION

Silvy LAPORTE, Présidente de la SFPT

**Stéphane MOULY, Vice-Président**

**Chantal BARIN-LE GUELLEC, Trésorière**

**Sébastien FAURE, Secrétaire Général**

**Véronique LAMARQUE-GARNIER**

Régis BORDET

Pascal BOUSQUET

François DAUPHIN

Jean DOUCET

François GUEYFFIER

Jean-Sébastien HULOT

Claire LE JEUNNE

Mathieu MOLIMARD

Jean-Louis MONTASTRUC

Catherine SGRO

## CONSEIL SCIENTIFIQUE

Régis BORDET, Président du Conseil Scientifique

**Cyril GOUDET, Vice-Président**

**Patrick ROSSIGNOL, Vice-Président**

Laurence DAULHAC-TERRAIL

Pierre-Olivier GIRODET

Karine LACUT

Silvy LAPORTE

Véronique LEBLAIS

Matthieu ROUSTIT

Françoise STANKE-LABESQUE

Céline VERSTUYFT

## COMITÉ LOCAL D'ORGANISATION

Pr Jean-Louis MONTASTRUC, Président du Comité Local d'Organisation

**Dr Maryse LAPEYRE-MESTRE**

**Pr Béatrice DULY-BOUHANICK**

**Pr Jean-Michel SENARD**

Avec l'aide de :

Pr Jacques AMAR

Dr Haleh BAGHERI

Pr Bernard CHAMONTIN

Dr Christine DAMASE

Dr Fabien DESPAS

Dr Geneviève DURRIEU

Pr Peggy GANDIA

Dr Pascale OLIVIER

Pr Olivier RASCOL

Pr Anne ROUSSIN

Dr Agnès SOMMET

**Un merci tout particulier pour :**

M. Jean-Michel DU PLANTIER

Mme Françoise MORELL

Mme Nathalie TROISLOUCHE

## SECRÉTARIAT DE LA SFPT

Florence GUENAND

# Ô mon país, Ô Toulouse...

## Mot de Bienvenue

Bienvenue à tous à Toulouse pour le congrès 2018 de la SFPT. L'idée de cette organisation résulte de l'attachement des pharmacologues et thérapeutes toulousains à la SFPT et aussi de l'opportunité d'inclure ces journées de travail, de rencontre et d'échanges scientifiques et humains dans l'EuroScience Open Forum 2018, rencontre interdisciplinaire sur la science et l'innovation en Europe. Dans ce cadre, Toulouse est "Cité européenne de la science" pour l'année 2018.

Nous avons souhaité, pour ce congrès, traiter des thèmes d'actualité comme la neuropharmacologie, l'oncopharmacologie ou encore des sujets plus méconnus de notre société, comme l'évaluation des dispositifs médicaux. Soucieux de l'impact sociétal du médicament, puisque, selon le mot du Professeur Paul Montastruc, "le Médicament se faufile partout", notre groupe a aussi fait une large place à la pharmacovigilance et à la pharmacologie sociale sans oublier les fondements de notre discipline, la méthodologie et la recherche fondamentale.

Nous vous invitons, à l'issue des journées de travail, à vous promener dans Palladia Tolosa (Cité de la sagesse). Découvrez les charmes de notre fière cité gasconne avec les rappers Bigflo et Oli: "*Ma ville, elle est rose mais ça tu le sais déjà...C'est vrai qu'elle est vulgaire mais elle a la douceur d'une grand-mère. Au fait, on dit chocolatine et au passage on t'emmerde! Y'a pas la mer, pas la forêt, pas la campagne... Elle a le Pont Neuf comme collier, la Grave comme boucles d'oreilles. Des poussières de briques comme fond de teint*". Ou bien, suivez les pas de notre troubadour local Claude Nougaro en découvrant "*l'eau verte du canal du Midi et la brique rouge des Minimes*". Allez au Capitole, où "*les ténors enrhumés tremblaient sous leurs ventouses*". Visitez l'église Saint-Sernin qui "*illumine le soir, d'une fleur de corail que le soleil arrose*". Rencontrez les toulousains avec leur "*torrent de cailloux (qui) roule dans (leur) accent*". Sachez découvrir notre "*ville rose*" avec son "*rouge et noir*" où la "*violence bouillonne jusque dans les violettes, où "l'Espagne... pousse un peu sa corne"*". "*Ici, même les mémés aiment la castagne*"!

**Professeur Jean-Louis MONTASTRUC**  
Pharmacologie Médicale

**Docteur Maryse LAPEYRE-MESTRE**  
Pharmacologie Médicale

**Professeur Béatrice DULY-BOUHANICK**  
Thérapeutique

**Professeur Jean-Michel SÉNARD**  
Pharmacologie Médicale

## MARDI 12 JUIN

A partir de 10h00	Accueil des participants			
10h30 - 12h00	Groupe de travail STP Salle Pous	Groupe de travail REVISE Amphi A	APNET Amphi B	Journée des CIC  Inserm <small>Institut national de la santé et de la recherche médicale</small>  Amphi Paul Montastruc
12h05 - 12h15	Ouverture du congrès Grand Amphi			
12h20 - 13h20	Lunch box Symposium AMGEN : Prise en charge du risque cardiovasculaire lipidique avec les anticorps monoclonaux anti-PCSK9 Salle Pous	Lunch box Symposium NOVARTIS : Recherche translationnelle et migraine Amphi A		
13h30 - 15h00	Actualités sur le médicament et actualités thérapeutiques Salle Pous	Pharmacologie moléculaire et préclinique Amphi A  Prix de Thèse Amphi A	Pharmaco-surveillance Grand Amphi	
15h00 - 16h30	Happy Hour Posters - Pause café			
16h30 - 18h00	Pharmacologie cardiovasculaire Salle Pous		Neuro-Psycho- Pharmacologie Grand Amphi	Pharmacologie clinique, méthodologie Amphi Paul Montastruc
18h00 - 19h30	Réunion AEPFP Salle Pous		Réunion CNPM Grand Amphi	Réunion APNET Amphi Paul Montastruc

## MERCREDI 13 JUIN (APRÈS-MIDI)

14h00 - 15h30	Thème transversal 2 : Onco-Pharmacologie Grand Amphi	
15h30 - 16h00	Pause café	
16h00 - 17h30	Thème transversal 2 : Onco-Pharmacologie Grand Amphi	
17h30 - 18h30	Assemblée Générale de la SFPT et Remise des Prix Grand Amphi	Conférence Grand Public : Médicaments : faut-il en avoir peur ?
18h30 - 19h30	Apéritif à la Mairie de Toulouse	
20h00	Soirée du congrès (cocktail dînatoire)	

## MERCREDI 13 JUIN (MATIN)

08h30 - 09h30	Communications libres Oncologie Salle Pous	Communications libres Pharmaco-surveillance Grand Amphi	Communications libres STP Amphi Paul Montastruc
09h30 - 11h00	Happy Hour Posters Pause café		
11h00 - 12h30	Thème transversal 1 : Actualités sur la Pharmacologie des Antiparkinsoniens Grand Amphi		
12h45 - 13h45	Lunch box Symposium NOVO NORDISK : Nouvelles approches thérapeutiques de la prise en charge du diabète actuelles et à venir Salle Pous	Lunch box Symposium NOVARTIS : Evolution des pratiques dans l'insuffisance cardiaque Amphi Paul Montastruc	

## JEUDI 14 JUIN

09h00 - 10h00	Sujet d'actualité - Levothyrox : variabilité pharmacologique ou variabilité sociétale ? Grand Amphi	Communications libres Amphi Paul Montastruc	Controverse STP : Suivi thérapeutique des antirétroviraux Salle Pous
10h00 - 10h30	Pause café		
10h30 - 12h00	Thème transversal 3 : Les dispositifs médicaux Grand Amphi	Communications libres Pharmacovigilance – Addictovigilance Amphi Paul Montastruc	
12h00 - 12h15	Clôture du congrès Grand Amphi		
12h15 - 12h30	Lunch box		
12h45 - 14h45	Atelier Médicaments et grossesse : Grand Amphi	Atelier DDI Predictor Amphi Paul Montastruc	Session validant la FC en expérimentation animale Salle Pous

## MARDI 12 JUIN

10h30 – 12h00 *Salle Pous*  SFAR

### Groupe de travail STP

Émission de recommandations sur l'usage des antibiotiques en réanimation

10h30 – 12h00 *Amphi A*

### Groupe de travail REVISE

#### (REflexion sur la VIGILANCE et la SÉCURITÉ dans les ESSAIS CLINIQUES)

Qualité et transparence des données de sécurité des essais cliniques académiques  
Comités de Surveillance Indépendants dans les essais cliniques académiques

10h30-12h00 *Amphi B*

### APNET

12h05 – 12h15 *Grand Amphi*

### Ouverture du congrès

12h20 – 13h20 *Amphi A*  NOVARTIS

### Symposium-déjeuner NOVARTIS : Recherche translationnelle et migraine

▪ Modérateur : Vincent LARRUE (Toulouse)

12h20 Avancées physiopathologiques dans la migraine – Anne DUCROS (Montpellier)

12h40 Actualités dans la prise en charge de la migraine – Michel LANTÉRI-MINET (Nice)

13h00 Discussion générale

12h20 – 13h20 *Salle Pous*  AMGEN

### Symposium-déjeuner AMGEN : Prise en charge du risque cardiovasculaire lipidique avec les anticorps monoclonaux anti-PCSK9 - De la pharmacologie à la pratique clinique

▪ Modérateurs : Atul PATHAK (Toulouse), Meyer ELBAZ (Toulouse)

12h20 PCSK9, de la découverte de la cible aux potentialités thérapeutiques - Catherine BOILEAU (Paris)

12h40 Mécanismes d'action et pharmacologie des mAb, biothérapies à haute valeur Technologique - Théodora BEJAN ANGOULVANT (Tours)

13h00 Enseignements cliniques récents et données de sécurité d'utilisation - Atul PATHAK (Toulouse)

13h30 - 15h00 *Grand Amphi*

### Pharmaco-Surveillance

▪ Modérateurs : Annie-Pierre JONVILLE-BERA (Tours), Haleh BAGHERI (Toulouse)

#### Conférence invitée

13h30 Mésusage du médicament : le mal français - Bernard BEGAUD (Bordeaux)

#### Communications libres

14h00 CO-001 - Impact of French Medicines Agency's communication on sodium valproate prescription in women of childbearing potential age – Adeline DEGREMONT (Rennes)

14h10 CO-002 - Utilisation of antiepileptic drugs in girls and women of childbearing potential in France  
Caroline HURAUULT-DELARUE (Toulouse)

14h20 CO-003 - Twitter® and the soon to be legendary #PharmacoQuiz : tools for a recreational continuing medical education? Hélène GÉNIAUX (Limoges)

14h30 CO-004 - A survey of medication errors in Auvergne Rhone-Alpes Region - Nathalie PARET (Lyon)

14h40 CO-005 - Frequent antiretroviral comedication interactions in the elderly HIV population : study from Nadis® - Delphine BOURNEAU-MARTIN (Angers)

14h50 CO-006 - Risk of drug-drug interactions in out-hospital drug dispensings in France: results from the DRUG-Drug Interaction Prevalence Study (DRUG-DIPS) – Louis LETINIER (Bordeaux)

13h30 - 15h00 *Amphi A*

### Pharmacologie moléculaire et pré-clinique

▪ Modérateurs : Benjamin GUILLET (Marseille), Nelly FROSSARD (Strasbourg)

#### Conférence invitée

13h30 RCPG et agonistes biaisés - Céline GALES (Toulouse)

#### Communications libres

14h00 CO-007 - Long-term cognitive impact of chronic benzodiazepine intake after treatment discontinuation in mice - Julie DEGUILL (Lille)

14h10 CO-008 - Different antinociceptive effect of fingolimod in two mouse models of multiple sclerosis with neuropathic pain - Amélie DÉMOSTHÈNES (Clermont-Ferrand)

14h20 CO-009 - PharmacoMRI imaging of 5-HT1A receptor biased agonists – Luc ZIMMER (Lyon)

### Prix de thèse

▪ Jury : Cyril GOUDET (Montpellier) et des membres du conseil scientifique

14h30 CO-010 - Complementary role of P2 and adenosine receptors in ATP induced-anti-apoptotic effects against hypoxia injury on endothelial cells - Catherine FELIU (Reims)

14h40 CO-011 - Antidiabetic activity of polyphenol metabolites: urolithins – Morgane BAYLE (Montpellier)

14h50 CO-012 - Study of skin microvascular dysfunction in Systemic sclerosis: a physiopathological, pharmacological and therapeutic approach – Florence GAILLARD-BIGOT (Marseille)

## 13h30 - 15h00 Salle Pous

### Actualités sur le médicament et actualités thérapeutiques

▪ Modérateurs : Stéphane MOULY (Paris), Patrick MISMETTI (Saint-Étienne)

#### Conférences invitées

- 13h30 Anticoagulants oraux directs et traitement de la maladie thrombo-embolique veineuse associée au cancer - Laurent BERTOLETTI (Saint-Etienne)
- 13h45 Les complications auto-immunes des immunothérapies anti-cancéreuses du groupe des inhibiteurs de checkpoint - Cécile YELNIK (Lille), Sophie GAUTIER (Lille)
- 14h00 Nutrition artificielle: impact des essais thérapeutiques récents - Pierre-François DEQUIN (Tours) et Fabienne TAMION (Rouen)
- 14h15 Prévention des néphropathies dues aux produits de contraste iodés - Bénédicte SAUTENET (Tours)
- 14h30 Le développement des chimiothérapies par voie orale en cancérologie digestive - Sylvain MANFREDI (Dijon)
- 14h45 Comment l'injection intra-vésicale de toxine botulique a révolutionné la prise en charge de la vessie neurologique - François GIULIANO (Paris)

## 15h00 – 16h30 Happy Hour Posters

Salle des Thèses : zones jaune, orange, rose, rouge, bleu clair, bleu foncé

Salle Camille Soula : zones grise, violette, beige, marron, verte

### Zone jaune

Modérateurs : Joëlle MICALLEF (Marseille),  
Caroline VICTORRI-VIGNEAU (Nantes)

- PM1 - 001 - Venlafaxine : the baby ecstasy? About cases reported to addictovigilance centers - Basile CHRÉTIEN (Caen)
- PM1 - 002 - Atypical antipsychotic misuse and adverse events: a review of the French Pharmacovigilance Database - Véronique PINZANI (Montpellier)
- PM1 - 003 - Research chemicals benzodiazepines: data analysis of the French addictovigilance network and review of the literature - Helene PEYRIERE (Montpellier)
- PM1 - 004 - Misuse of medicines containing codeine used for self-medication and community pharmacists - Amélie DAVELUY (Bordeaux)
- PM1 - 005 - Trends in analgesics consumption in France, 2006-2015, and comparison of patterns across Europe - Karima HIDER MLYNARZ (Saint Denis)
- PM1 - 006 - Assessment of diverted use of psychoactive drugs by adolescents and young adults in community pharmacies - Emilie JOUANJUS (Toulouse)
- PM1 - 007 - Analgesic consumption in subjects with substance use disorder - Camille PONTÉ (Toulouse)

### Zone orange

Modérateurs : Luc ZIMMER (Lyon),  
Thavarak OUK (Lille)

- PM1 - 008 - Microscopic colitis and non-steroidal anti-inflammatory drugs. - Brahim AZZOUZ (Reims)
- PM1 - 009 - Atypical Hemolytic Uremic Syndrome (aHUS) after short-term ketoprofen treatment: about 2 cases - Jean-Luc FAILLIE (Montpellier)
- PM1 - 010 - Harm signal: 5 cases of serious painful musculoskeletal syndrome among 79 patients treated with teriflunomide - Laure PEYRO-SAINTE-PAUL (Caen)
- PM1 - 011 - Cardiovascular safety of methylphenidate in adult attention deficit hyperactivity disorder (ADHD): the Lille experience - Camille POTEY (Lille)
- PM1 - 012 - Immunomodulatory imide drugs and progressive multifocal leukoencephalopathy: about 4 cases - Jean-Luc FAILLIE (Montpellier)
- PM1 - 013 - Gaucher disease : French cohort of the 58 patients treated by eliglustat - Céline VERSTUYFT (Le Kremlin-Bicêtre)

## Zone rose

Modérateurs : Marion LEPELLEY (Grenoble),  
Franck ROUBY (Marseille)

- PM1 - 014 - Nicorandil-induced ulcerations: A 10-year observational study of spontaneously reported cases to the French pharmacovigilance network. - Nadine PETITPAIN (Nancy)
- PM1 - 015 - Drug-induced anaphylaxis in the French and Vietnamese pharmacovigilance databases 2010-2015 : a social pharmacological discussion - Khac-Dung NGUYEN (Toulouse)
- PM1 - 016 - Evaluation of a "hybrid" e-learning approach based on peer-evaluation in the field of pharmacovigilance, drug-drug interactions and drug contraindications - Roland Fabrice LAWSON (Limoges)
- PM1 - 017 - Paradoxical injunctions get along with quality insurance in pharmacovigilance - Sofia BERRIRI (Nice)
- PM1 - 018 - Drug related deaths : retrospective analysis in a French university hospital - Marion LEPELLEY (Grenoble)
- PM1 - 019 - Underreporting of adverse drug reactions (ADRs) from Skilled nursing homes (SNH): Survey in the Loire department to identify obstacles and suggest improvement measures. - Olivia THAO-THIEBAUT (Saint-Etienne)
- PM1 - 020 - Comparison of Patients' and Retail Pharmacies' Adverse Drug Reaction Reports to a Regional Pharmacovigilance Regional Centre - Haleh BAGHERI (Toulouse)

## Zone rouge

Modérateurs : Florentia KAGUELIDOU (Paris),  
Sihem BENABOUD (Paris)

- PM1 - 021 - Trends of sodium valproate prescriptions in children 0 to 14 years of age between 2010 and 2016: study from the French National Health Insurance Databases - Elisabeth POLARD (Rennes)
- PM1 - 022 - Drug reaction with eosinophilia and systemic symptoms in Pediatric Patients: a French nationwide study - Annie-Pierre JONVILLE-BERA (Tours)
- PM1 - 023 - Transversus abdominis plane block with levobupivacaine : first results of pharmacokinetics in pediatric patients - Olivier MATHIEU (Montpellier)
- PM1 - 024 - Continuous infusion of vancomycin in critically ill children: do we achieve the target? Sihem BENABOUD (Paris)
- PM1 - 025 - Early Bayesian dose adjustment of vancomycin in children : a randomized controlled trial - Jean-Marc TRELUYER (Paris)
- PM1 - 026 - Trends in the use of analgesic opioids in pediatric patients: impact of safety recommendations - Nicolas AUTHIER (Clermont-Ferrand)
- PM1 - 027 - Assessment of methotrexate serum concentrations in children with acute lymphoblastic leukemia - Souha BEN TEKAYA (Tunis)

## Zone bleu clair

Modérateurs : Véronique LEBLAIS (Paris),  
Pascal BOUSQUET (Strasbourg)

- PM1 - 028 - Thromboembolic events in women exposed to hormonal contraception: regional comparison with data from the national pharmacovigilance survey carried out in 2012 and evaluation of prescription practices after new national guidelines. - Marie-Blanche VALNET-RABIER (Besançon)
- PM1 - 029 - The effectiveness of oral anticoagulants in the prevention of stroke in patients with non-valvular atrial fibrillation: results from the Stroke Prevention and Anticoagulants (SPA) study - Lamiae GRIMALDI-BENSOUDA (Paris)
- PM1 - 030 - Comparative patterns of use of direct oral anticoagulants and vitamin K antagonists and risk of haemorrhage in real life - Lamiae GRIMALDI-BENSOUDA (Paris)
- PM1 - 031 - A safety signal of venous thromboembolic events with the use of DPP-4 inhibitors: a pharmacovigilance disproportionality analysis - Amandine GOUVERNEUR (Bordeaux)
- PM1 - 032 - Reports of Adverse events with levonorgestrel IUD Mirena in France before and after the 2017 media intense coverage - Amandine GOUVERNEUR (Bordeaux)
- PM1 - 033 - P-glycoprotein (P-gp) antagonists may increase dabigatran plasma levels and bleeding occurrence in very elderly patients in usual conditions of care - Marjorie BERNIER (Nice)
- PM1 - 034 - Retrospective analysis of seven years of heparin induced thrombocytopenia (HIT): a one center experience - Virginie FULDA (Paris)

## Zone bleu foncé

Modérateurs : Pierre-Olivier GIRODET (Bordeaux),  
Matthieu ROUSTIT (Grenoble)

- PM1 - 035 - Intoxication with baclofen: is haemodialysis indicated? - Peggy GANDIA (Toulouse)
- PM1 - 036 - Combination of Piperacillin-Tazobactam and Vancomycin with a risk of Acute Kidney Injury: a french pharmacovigilance survey - Judith COTTIN (Lyon)
- PM1 - 037 - Factors associated with medium-low compliance in patients suffering from treatment resistant mood disorders - Caroline VICTORRI-VIGNEAU (Nantes)
- PM1 - 038 - Drug Pain treatment and Fibromyalgia : Panacea or snake oil? - Alexanne ACHARD (Clermont-Ferrand)
- PM1 - 039 - Hemolytic anemia and artemisinin derivatives: a case series - caroline JOYAU (Nantes)
- PM1 - 040 - Effect of varenicline on smoking cessation in COPD patients recovering from exacerbation: a randomized trial - raphael LE MAO (Brest)
- PM1 - 041 - Do patients in therapeutic failure, receiving mu opioid agonist for pain or addictive care, share the same characteristics? MUSIC -receptor mu and genetic- study - Caroline VICTORRI-VIGNEAU (Nantes)

## Zone grise

Modérateurs : Fabien DESPAS (Toulouse),  
Mathieu MOLIMARD (Bordeaux)

- PM1 - 042 - Trough dabrafenib plasma concentrations can predict occurrence of adverse effects requiring dose reduction in metastatic melanoma. - Marine ROUSSET (Bordeaux)
- PM1 - 043 - A targeted genomic analysis uncovered a large spectrum of acquired resistance mechanisms to BRAF inhibitor therapy in metastatic melanoma patients - Baptiste LOUVEAU (Paris)
- PM1 - 044 - Implementing routine pre-emptive DPD testing with adaptive dosing to secure 5-FU administration: Performance in digestive and head and neck cancer patients - Manon LAUNAY (Paris)
- PM1 - 045 - Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders - Jean-Jacques TUDESQ (Montpellier)
- PM1 - 046 - 5-fluorouracil and hyperammonemia - Julie LEBRUN (Montpellier)
- PM1 - 047 - Real-life tolerance and plasma exposure assessment of lenvatinib in thyroid metastatic cancer patients - Lauriane GOLDWIRT (Paris)
- PM1 - 048 - Biological monitoring of occupational exposure to 5-fluorouracil by urinary  $\alpha$ -fluoro- $\beta$ -alanine assay with a high sensitivity analytical method - Mathieu MOLIMARD (Bordeaux)

## Zone violette

Modérateurs : Jérémy BELLIEU (Rouen),  
Cyril GOUDET (Montpellier)

- PM1 - 049 - Serotonin 2B receptor potentiates erythropoietin-induced mobilization of endothelial progenitor cells: contribution to hypoxic pulmonary arterial hypertension? - Estelle AYME-DIETRICH (Strasbourg)
- PM1 - 050 - Effect of the iontophoresis of a prostacyclin analog on wound healing in a murine model of diabetes - Yann SAVINA (Grenoble)
- PM1 - 051 - Endothelial cells exposed to uremic toxins secrete interleukin-8 which promotes vascular calcifications - Youssef BENNIS (Amiens)
- PM1 - 052 - Encapsulation of prostacyclin analogs in lipid nanoparticles for the local treatment of skin ulcerations: formulation and pharmacokinetics. - Raphaël BOUVET (Grenoble)
- PM1 - 053 - Effects of pharmacological inhibition of the hydrolase activity of soluble epoxide hydrolase in a murine model of pulmonary hypertension associated or not with cardiac insufficiency. - Matthieu LEUILLIER (Rouen)

## Zone beige

Modérateurs : Laurent BECQUEMONT (Paris),  
Nicolas TOURNIER (Orsay)

- PM1 - 054 - Endogenous metabolites-mediated communication between OAT1/OAT3 and OATP1B1 may explain the association between SLCO1B1 SNPs and methotrexate toxicity - chantal BARIN-LE GUELLEC (Tours)
- PM1 - 055 - Simultaneous cocktail phenotyping of CYP450-mediated drug metabolism in patients with inappropriate response to psychotropic drugs - Xavier DECLÈVES (Paris)
- PM1 - 056 - Comparison of validated Caco-2 and MDCKs in vitro cell models for drug transport studies - Elodie JACQUEROUX (Saint-Etienne)
- PM1 - 057 - Evaluation of a strategy to enhance the brain distribution of erlotinib: a [11C]erlotinib PET imaging study in nonhuman primates - Nicolas TOURNIER (Orsay)
- PM1 - 058 - Cirrhotic patients, especially those with neurological symptoms, display dramatically increased levels of several xenobiotics in plasma, a metabolomic study - Nicolas WEISS (Paris)
- PM1 - 059 - How pharmacogenetics effects disappear over time : SLCO1B1 polymorphism and early discontinuation of statin therapy after acute myocardial infarction - Laurent BECQUEMONT (Le Kremlin-Bicêtre)

## Zone marron

Modérateurs : Françoise STANKE (Grenoble),  
Fabien LAMOUREUX (Rouen)

- PM1 - 060 - ITPA activity: Relation to thiopurine metabolites and TPMT activity - Roselyne BOULIEU (Lyon)
- PM1 - 061 - Liquid chromatography/ mass spectrometry and pharmacokinetic modelling as complementary tools for the personalization of infliximab treatment. - Benjamin NEMOZ (Grenoble)
- PM1 - 062 - Dried blood spot for therapeutic drug monitoring of ciclosporin - Véronique LELONG-BOULOUARD (Caen)
- PM1 - 063 - Development of a Population Pharmacokinetic model and a Bayesian Estimator for estimation of Everolimus Whole Blood and Intra-lymphocyte Exposure in Renal Transplant Recipients - Jean-Baptiste WOILLARD (Limoges)
- PM1 - 064 - Interest of therapeutic drug monitoring of tacrolimus in bile matrix in liver transplant recipients: the STABILE study. - Camille TRON (Rennes)
- PM1 - 065 - Clinical impact of reassessed tacrolimus starting dose according to CYP3A5 genotype in kidney transplant recipients - Chantal BARIN-LE GUELLEC (Tours)



## Zone verte

Modérateurs : Lamiae GRIMALDI-BENSOUDA (Paris),  
Agnès SOMMET (Toulouse)

- PM1 - 066 - Impact of medication reconciliation on the sustainability of post-hospitalization prescriptions - Aurélie DAUMAS (Marseille)
- PM1 - 067 - Prevalence of inappropriate drug prescription in patients with chronic kidney disease and the impact of equation used to estimate kidney function - Sophie LIABEUF (Amiens)
- PM1 - 068 - Misuse of strong opioids in patients with cancer in the last year of life - Manuela RUETER (Toulouse)
- PM1 - 069 - Nonagenarians presenting to the emergency department after falls-related drug use: characteristics and outcomes - Jacques BOUGET (Rennes)
- PM1 - 070 - Prevalence and factors associated with medical drug purchase in the streets of Port-au-Prince, Haiti - Ydrif Léonard FRETT (Port-Au-Prince)
- PM1 - 071 - Medication errors involving single dose pods before and after an information campaign - Farid KHELOUFI (Marseille)

## MARDI 12 JUIN

16h30 - 18h00 *Salle Pous*

### Pharmacologie cardiovasculaire

▪ Modérateurs : Jean-Michel SENARD (Toulouse), Vincent RICHARD (Rouen)

#### Conférence invitée

16h30 Inhibiteurs d'arginase et dysfunction endothéliale - Céline DEMOUGEOT (Besançon)

#### Communications libres

- 17h00 CO-013 - Diabetes, Statins, Fibrates and their association - Jean-Louis MONTASTRUC (Toulouse)
- 17h10 CO-014 - Bleeding Complications and Antithrombotic Treatment in 264 Pregnancies in Antiphospholipid Syndrome - Cécile M. YELNIK (Lille)
- 17h20 CO-015 - Short- and long-term imeglimine treatment reduces metabolic syndrome-related diabetic coronary and peripheral endothelium dysfunction - Marianne LACHAUX (Rouen)
- 17h30 CO-016 - Bradykinin-mediated angioedema associated with combination of angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: a disproportionality analysis from the WHO database - Marion LEPELLEY (Grenoble)
- 17h40 CO-017 - Population pharmacokinetic-pharmacodynamic model of oral fludrocortisone on blood pressure after six days of repeated administration in healthy volunteers Nouredine HAMITOUCHE (Rennes)
- 17h50 CO-018 - Statins and new-onset diabetes - Julien BEZIN (Bordeaux)

16h30 - 18h00 *Grand Amphi*

### NeuroPsychoPharmacologie

▪ Modérateurs : Alain ESCHALIER (Clermont-Ferrand), Michel PLOTKINE (Paris)

#### Conférence invitée

16h30 Récepteurs A2A et maladies neurodégénératives - David BLUM (Lille)

#### Communications libres

- 17h00 CO-019 - A barrier or a pump? Imaging the impact of P-glycoprotein function on the brain kinetics of metoclopramide in nonhuman primates - Nicolas TOURNIER (Orsay)
- 17h10 CO-020 - Patterns and profiles of Methylphenidate use in adults: A cohort study from the regional French health insurance database - Joëlle MICALLEF (Marseille)
- 17h20 CO-021 - Impact of infusion-based therapies initiation on levodopa equivalent daily dose in advanced Parkinson's disease patients: a 2-year retrospective study in a french expert center. Guillaume HACHE (Marseille)
- 17h30 CO-022 - Role of serotonin transporter in antidepressant-induced diabetes: A pharmacoepidemiologic - pharmacodynamic study in VigiBase® - Thi Thu Ha NGUYEN (Toulouse)
- 17h40 CO-023 - Trends and patterns of antidepressant use in French children and adolescents from 2009 to 2016: a French paradox? - Alexis REVET (Toulouse)
- 17h50 CO-024 - Framing off-label prescribing : CAMTEA device for methylphenidate use in adult ADHD Louise CARTON (Lille)

## 16h30 - 18h00 Amphi Paul Montastruc

### Pharmacologie clinique, méthodologie

- Modérateurs : Behrouz KASSAI (Lyon), Francesco SALVO (Bordeaux)

#### Conférence invitée

16h30 Les comités de surveillance dans les essais cliniques - Silvy LAPORTE (Saint-Etienne)

#### Communications libres

- 17h00 CO-025 - Comparison of randomized controlled trials and cohort studies for the assessment of direct oral anticoagulants (DOAC) - Silvy LAPORTE (Saint-Etienne)
- 17h10 CO-026 - Data sharing and re-analysis for randomised clinical trials in journals with a strong data sharing policy - Florian NAUDET (Rennes)
- 17h20 CO-027 - Safety evaluation of the levonorgestrel intrauterine device Mirena® from the French nationwide claims and hospitalization database - Amandine GOUVERNEUR (Bordeaux)
- 17h30 CO-028 - Channelling in users of antiplatelet agents and consequences for relative risk and relative effectiveness assessment - Lamiae GRIMALDI-BENSOUA (Paris)
- 17h40 CO-029 - Are current guidelines adapted for patient eligibility to PrEP? Elise K VAN OBBERGHEN (Nice)
- 17h50 CO-030 - Toward a disparition of antitumoral effect of low molecular weight heparin (LMWH) in cancer patients since the first trials - Edouard OLLIER (Saint-Etienne)

## 18h00 - 19h30 Grand Amphi

### Réunion CNPM

## 18h00 - 19h30 Salle Pous

### Réunion AEPFP

## 18h00 - 19h30 Amphi Paul Montastruc

### Réunion APNET

## 10h00 - 16h00 Amphi Paul Montastruc

### Journée des CIC Institut national de la santé et de la recherche médicale

## 09h00 - 10h00

### Accueil café

### Ouverture : Dominique Deplanque

## 10h00

### Table ronde: La position des CIC dans les "Groupement Hospitalier de Territoire" GHT

Dominique Mottier, *CIC de Brest* - Marc Bardou, *CIC de Dijon* - Anthony Chapron, *CIC de Rennes* - Odile Séchoy, *Directrice de la Recherche et de l'Innovation du CHU de Toulouse*

Discussion avec les participants à la journée

- Président de séance : Hélène Espérou

## 11h00

Réseaux F-CRIN et interactions avec les réseaux thématiques des CIC

Olivier Rascol *CIC de Toulouse* et Coordinateur de F-CRIN

Le nouveau bureau national : qui et pour quoi faire ?

Dominique Deplanque, *Coordinateur du réseau National des CIC*

## 12h00 - 13h30

### Pause déjeuner

## 13h30

- Président de séance : Olivier Rascol

### Projets

- Opportunités de financements européens et exemple d'un projet financé - Sophie Decamps, *chargée de mission, Pôle Relations Européennes, DPPE, Inserm*

- Ecole d'été EIT Health - Isabelle Marque, *Coordination du Réseau National des CIC-IT*

Cohorte familiale Stanislas, 4<sup>e</sup> visite à 20 ans : recherche de biomarqueurs associés avec l'apparition d'une hypertrophie ventriculaire gauche - Patrick Rossignol, *CIC de Nancy*

Programme de thérapie génique du cancer du pancréas : essai transformé - Louis Buscail, *CIC de Toulouse*

## 15h15

### Qualité et CIC

Bilan des actions du groupe QUALI-CIC

Catherine Cornu, *CIC de Lyon* et Claire Thalarnas, *CIC de Toulouse*

Comment évaluer de façon simple la satisfaction des patients et volontaires sains d'un CIC ?

Adeline Paris, *CIC de Grenoble*

## 16h00

### Clôture

## MERCREDI 13 JUIN

### 08h30 - 09h30 Salle Pous

#### Communications libres - Thème Oncologie

▪ Modérateurs : Samia MOURAH (Paris), Chantal BARIN LE GUELLEC (Tours)

##### Communications libres

- 08h30 CO-031 - Population pharmacokinetics and probability of target attainment of mitotane in patients with adrenocortical carcinoma - Yoann CAZAUBON (Reims)
- 08h40 CO-032 - Cetuximab Pharmacokinetic/Pharmacodynamics relationships in metastatic HNSCC patients - Félicien LE LOUEDEC (Toulouse)
- 08h50 CO-033 - Use of 5 $\alpha$ -reductase inhibitors for benign prostate hypertrophy and risk of high-grade prostate cancer: A French population-based study. - Lucie-Marie SCAILTEUX (Rennes)
- 09h00 CO-034 - Imaging the impact of OATP function on erlotinib exposure to tissues: a 11C-erlotinib PET study in rats - Nicolas TOURNIER (Orsay)
- 09h10 CO-035 - Prediction of unbound carboplatin clearance from total plasma concentration to simplify dose adaptation based on therapeutic drug monitoring - Sotheara MOEUNG (Toulouse)
- 09h20 CO-036 - Use, safety and effectiveness of targeted therapies in colorectal cancer according to age and frailty - Amandine GOUVERNEUR (Bordeaux)

### 08h30 - 09h30 Grand Amphi

#### Communications libres - Thème pharmaco-surveillance

▪ Modérateurs : Bénédicte LEBRUN-VIGNES (Paris), Amélie DAVELUY (Bordeaux)

##### Communications libres

- 08h30 CO-037 - vaccine practices during the first year of life in children born to mothers with inflammatory bowel disease. Retrospective cohort on the French national health insurance database  
Maxime LUU (Dijon)
- 08h40 CO-038 - Tamoxifen exposure during pregnancy, a descriptive analysis based on Terappel  
Veronique PIZZOGLIO (Lyon)
- 08h50 CO-039 - Adverse drug reactions on male fertility: a study in VigiBase® - Isabelle LACROIX (Toulouse)
- 09h00 CO-040 - Drug-Induced Aseptic Meningitis: 320 cases from the French Pharmacovigilance DataBase Analysis - Kevin BIHAN (Paris)
- 09h10 CO-041 - Misuse of analgesics in the context of self-medication: results of a large cross-sectional survey from the DANTE study (Une Décennie d'ANTalgiques En France)  
Marylene GUERLAIS (Nantes)
- 09h20 CO-042 - Drug-induced retroperitoneal fibrosis: could antidepressants be involved?  
Diana BRASSELET (Paris)

### 08h30 - 09h30 Amphi Paul Montastruc

#### Communications libres - Thème STP

▪ Modérateurs : Stéphane BOUCHET (Bordeaux), Frédéric LIBERT (Clermont-Ferrand)

##### Communications libres

- 08h30 CO-043 - High inpatient variability of tacrolimus exposure is associated with poorer outcomes after liver transplantation - Florian LEMAITRE (Rennes)
- 08h40 CO-044 - A multiplex and easy-to-perform liquid chromatography tandem mass spectrometry method for the quantification of 7 therapeutic monoclonal antibodies - Jean-Francois JOURDIL (Grenoble)
- 08h50 CO-045 - Complex target-mediated elimination of rituximab in non-Hodgkin's Lymphoma patients - David TERNANT (Tours)
- 09h00 CO-046 - Population pharmacokinetics of enoxaparin in early stage of pediatric liver transplantation - Jean-Marc TRÉLUYER (Paris)
- 09h10 CO-047 - Gene polymorphism of P-glycoprotein as a determinant of daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection - Sylvain GOUTELLE (Lyon)
- 09h20 CO-048 - Inflammation is the main risk factor for supratherapeutic levels of voriconazole in hematological patients - Elodie GAUTIER-VEYRET (Grenoble)

## 09h30 – 11h00 Happy Hour Posters

*Salle des Thèses : zones jaune, orange, rose, rouge, bleu clair, bleu foncé*

*Salle Camille Soula : zones grise, violette, beige, verte*

### Zone jaune

Modérateurs : Louise CARTON (Lille),  
Hélène PEYRIERE (Montpellier)

- PM2 - 001 - Pharmacovigilance of opioids analgesics : a pharmacoepidemiological study using doctor shopping indicator in French health Insurance database - Joelle MICALLEF (Marseille)
- PM2 - 002 - Evaluation of possible addiction among migrant women consuming kaolin in metropolitan France: a pilot study - Caroline VICTORRI-VIGNEAU (Nantes)
- PM2 - 003 - Opioid maintenance therapy in France: high-dosage buprenorphine still predominant despite a high increase in methadone use: results from the 2009-2015 UTOPIA study - Sandy MAUMUS-ROBERT (Bordeaux)
- PM2 - 004 - Off-label use of oral morphine sulfate for opioid maintenance purpose in France: results from the 2009-2015 UTOPIA study - Sandy MAUMUS-ROBERT (Bordeaux)
- PM2 - 005 - Nine years of Methadone post marketing surveillance from the French addictovigilance network data - Elisabeth FRAUGER (Marseille)
- PM2 - 006 - interactions between buprenorphine and benzodiazepines promote prolonged opioid dependence - Antoine COQUEREL (Caen)
- PM2 - 007 - Unintentional prescription opioid overdose-related hospitalizations in France: an emerging signal ? Nicolas AUTHIER (Clermont-Ferrand)

### Zone orange

Modérateurs : Olivier BLIN (Marseille),  
Laurent TRITSCHLER (Paris)

- PM2 - 008 - Pharmacokinetics of baclofen in alcoholic-dependent patients with cirrhosis - Xavier DECLÈVES (Paris)
- PM2 - 009 - Baclofen and sleep apnoea syndrome: analysis of VigiBase® the WHO pharmacovigilance database - Bruno REVOL (Grenoble)
- PM2 - 010 - Neuromuscular Blocking Agents induced anaphylaxis: the French pharmacovigilance experience from 2000 to 2012 - Nadine PETITPAIN (Nancy)
- PM2 - 011 - TNF inhibitors and amyotrophic lateral sclerosis: a risk factor ? Nadine PETITPAIN (Nancy)
- PM2 - 012 - Neurological impairment in cirrhotic patients admitted to ICU: hepatic or drug-induced encephalopathy ? Nicolas WEISS (Paris)
- PM2 - 013 - Long-term antidepressant treatment and valvular heart disease? Romain DE JORNA (Montpellier)

### Zone rose

Modérateurs : Antoine PARIENTE (Bordeaux),  
Emilie BOUQUET (Tours)

- PM2 - 014 - Serious drug adverse reactions: A retrospective and descriptive study from the French regions of Bordeaux, Limoges, and Poitiers - Amandine GOUVERNEUR (Bordeaux)
- PM2 - 015 - A week for patient safety: "All actors, all vigilant" - Anaïs GAIFFE (Besançon)
- PM2 - 016 - Prescribing practices for the elderly in Residential Care homes for the Elderly (EHPAD): a pharmacological approach of the PAAPI (Elderly patients & Inappropriate Prescriptions) program - Haleh BAGHERI (Toulouse)
- PM2 - 017 - Anticholinergic drug use and risk for age-related macular degeneration: a case-control study - Gauthier ALDEBERT (Montpellier)
- PM2 - 018 - Psoriasis during angiotensin receptor blocker exposure : a case/non case study using the French Pharmacovigilance Database. - Brahim AZZOUZ (Reims)
- PM2 - 019 - The era of pharmacovigilance - Malak ABOU TAAM (Saint-Denis)
- PM2 - 020 - Evaluation of online discussion forums as a complementary source of data for pharmacovigilance: the Vigi4MED project - Florelle BELLET (Saint-Etienne)

### Zone rouge

Modérateurs : Isabelle LACROIX (Toulouse),  
Thierry VIAL (Lyon)

- PM2 - 021 - Pregnant women need more information on paracetamol: a survey in 480 expecting women - Julie VILLECOURT (Clermont-Fd)
- PM2 - 022 - Medical care of pregnant women treated by sodium valproate : observational study from the french medico-administrative database from 2011 to 2016. - Adeline DEGREMONT (Rennes)
- PM2 - 023 - Analysis of the new POMME cohort data: drug exposure in children from the first day of the intrauterine life until 6 years old - Justine BENEVENT (Toulouse)
- PM2 - 024 - Single administration of amiodarone by intravenous route and breastfeeding - Lucie JAVOT (Nancy)
- PM2 - 025 - Non-steroidal anti-inflammatory drugs (NSAIDs) prescriptions after the 6th month of pregnancy: impact of health authorities' advice - Mélanie ARAUJO (Toulouse)
- PM2 - 026 - In utero drug exposure and hearing disorders in 2-year-old children: A case-control study using the EFEMERIS database - Isabelle LACROIX (Toulouse)
- PM2 - 027 - Analysis of data on exposure to modafinil during pregnancy - Marion LEPELLEY (Grenoble)

## Zone bleu clair

Modérateurs : Jean-Luc CRACOWSKI (Grenoble), Laurent BERTOLETTI (Saint-Etienne)

PM2 - 028 - Adverse drug reactions reported with antialdosterones to French Pharmacovigilance database - Sophie FEDRIZZI (Caen)

PM2 - 029 - Acute hypotensive and chronic treatments effects of *Phyllanthus amarus* (Euphorbiaceae) on blood pressure, cardiac and endothelial function in normotensive rabbits and DOCA-salt hypertensive rats - Alain N'guessan YAO (Abidjan)

PM2 - 030 - Comparative effectiveness of statins in cardiovascular secondary prevention - Jordan GUILLOT (Bordeaux)

PM2 - 031 - Association of the SLC01B1 Haplotypes with myopathies under statins - Marwa AJMI (Sousse)

PM2 - 032 - US cholesterol guidelines do not fit French population - François GUEYFFIER (Lyon)

PM2 - 033 - Should cardiovascular deaths be frequent enough to observe a mortality decrease with statins ? A meta-regression approach. - François GUEYFFIER (Lyon)

## Zone bleu foncé

Modérateurs : Dominique DEPLANQUE (Lille), Sophie DURANTON (Poitiers)

PM2 - 034 - ISO 9001:2015 certification: Grenoble hospital's clinical research and innovation delegation experience - Camille DUCKI (La Tronche)

PM2 - 035 - Cost-effectiveness of full versus targeted monitoring of randomized controlled trials - Claire FOUGEROU-LEURENT (Rennes)

PM2 - 036 - Impact of clinical trial requalification on safety management due to new French regulation - Clémence PONCET (Lyon)

PM2 - 037 - Overlapping network meta-analyses on the same topic - Florian NAUDET (Rennes)

PM2 - 038 - Interest of Data and Safety Monitoring Boards (DSMB) for category 1 clinical studies - Anthony FACILE (Lyon)

## Zone grise

Modérateurs : Bruno LAVIOLLE (Rennes), Nicolas CLERE (Angers)

PM2 - 039 - Neuroprotective effect of Angiotensin II type 2 receptor stimulation in vincristine-induced sensory neuropathy - Claire DEMIOT (Limoges Cedex)

PM2 - 040 - Ropoginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial - Lydia ROY (Créteil)

PM2 - 041 - Adverse effects of oral anticancer medications reported by patients from a clinical centre of oral therapies in Limoges: a descriptive analysis. - Hélène GÉNIAUX (Limoges)

PM2 - 042 - Tyrosine kinase inhibitors and digestive perforation: all responsible? Camille POTEY (Lille)

PM2 - 043 - Combination of Dasatinib and Peg-Interferon alpha 2b in Chronic Phase Chronic Myeloid Leukemia first line: 24-Months results of a Phase II academic trial - Lydia ROY (Créteil)

PM2 - 044 - Evaluation of the Use of Apixaban in Prevention of Thromboembolic Disease in Patients With Myeloma Treated With iMiDs - Marylaure GAVARD (Grenoble)

PM2 - 045 - Post-marketing evaluation of medications in oncogeriatry: application to the treatment of metastatic colorectal cancer - Amandine GOUVERNEUR (Bordeaux)

## Zone violette

Modérateurs : Christian FUNCK BRENTANO (Paris), Karine LACUT (Brest)

PM2 - 046 - Reversible cerebral vasoconstriction syndrome (RCVS) and vasoactive drugs: analysis in the French pharmacovigilance database (FPD) and review of literature - Gwenaëlle VEYRAC (Nantes)

PM2 - 047 - Risk of stroke and myocardial infarction in users of vasoconstrictor drugs for ear, nose and throat related conditions - Lamiae GRIMALDI-BENSOUDA (Paris)

PM2 - 048 - Bladder cancers associated with gliflozin use: a case - non case analysis in the World Health Organization's adverse drug reactions database - Sylvie DA SILVA (Montpellier)

PM2 - 049 - Drug-induced pulmonary arterial hypertension: a case-control study on VigiBase® - Marie-Laure LAROCHE (Limoges)

PM2 - 050 - Safety profile of sclerosing agents: an analysis from the world health organization pharmacovigilance database Vigibase®. - Charles KHOURI (Grenoble)

## Zone beige

Modérateurs : Marie-Clémence VERDIER (Rennes),  
Xavier DELAVENNE (Saint-Etienne)

- PM2 - 051 - Quantitative prediction of drug interaction with the DDI-predictor web-tool : a case study with the emergency contraceptive ulipristal - Claire LE CORVAISIER (Lyon)
- PM2 - 052 - A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy - Christelle RODRIGUES (Paris)
- PM2 - 053 - A pilot evaluation of the Population pharmacokinetics of vigabatrin enantiomers in infants and young children with epilepsy receiving a new soluble tablet form of vigabatrin. - Marwa OUNISSI (Paris)
- PM2 - 054 - Influence of trough serum concentration on blood pressure rise in cancer patients treated with bevacizumab - Theodora BEJAN-ANGOULVANT (Tours)
- PM2 - 055 - Forecasting drug-drug interactions for new drugs using the in vivo mechanistic static model: netupitant as a case study - Sylvain GOUTELLE (Lyon)
- PM2 - 056 - Population pharmacokinetics of articaine with 1:200,000 epinephrine during third molar surgery and simulation of high-dose regimens - Yoann CAZAUBON (Reims)
- PM2 - 057 - Valproate levels according in children to age - Rim CHARFI (Tunis)

## Zone verte

Modérateurs : Florian LEMAITRE (Rennes),  
Vincent JULLIEN (Paris)

- PM2 - 058 - Model Based Meta-Analysis of Vancomycin Clearance during Renal Replacement Therapy: Application to Vancomycin pharmacokinetic during SLED in ICU patients - Edouard OLLIER (Saint Etienne)
- PM2 - 059 - Darunavir unbound concentrations in plasma, not total concentration is the relevant concentration to predict darunavir efficacy in subject of different body mass index. - David METSU (Toulouse)
- PM2 - 060 - Cefotaxime dosing regimen optimization in critically ill children - Sihem BENABOUD (Paris)
- PM2 - 061 - Achievement of vancomycin AUC targets: a study in elderly patients - Vincent LECLERC (Lyon)
- PM2 - 062 - Pharmacokinetics of ofloxacin in osteo-articular infected patients: should we consider therapeutic drug monitoring? - Florian LEMAITRE (Rennes)

## MERCREDI 13 JUIN

11h00 - 12h30 *Grand Amphi*

### Thème transversal 1 : Actualités sur la Pharmacologie des Antiparkinsoniens

- Modérateurs : Luc ZIMMER (Lyon), Olivier BLIN (Marseille)

#### Conférences invitées

- 11h00 Quelques leçons de Pharmacologie Clinique après 50 ans de L-DOPA – Olivier RASCOL (Toulouse)
- 11h30 Maladie de Parkinson: Aspects Pharmacogénétiques - Jean-Christophe CORVOL (Paris)
- 12h00 Maladie de Parkinson: Modèles expérimentaux et translations cliniques - Erwan BEZARD (Bordeaux)



12h45 - 13h45 *Salle Pous* novo nordisk

### Symposium-déjeuner NOVO NORDISK: Nouvelles approches thérapeutiques de la prise en charge du diabète actuelles et à venir : les analogues du GLP-1

- Modérateur : Béatrice DULY-BOUHANICK (Toulouse)

- 12h45 Du mode d'action du GLP1 aux conséquences pratiques - Rémy BURCELIN (Toulouse)
- 13h00 Les aspects cliniques des analogues du GLP1 au travers leur développement clinique et les études CVOT avec les entités actuelles et à venir - Pierre GOURDY (Toulouse)
- 13h30 Traitement du diabète de type 2 dans différentes populations : à partir des recommandations actualisées de la Société Française de Diabétologie - Béatrice DULY-BOUHANICK (Toulouse)

12h45 - 13h45 *Amphi Paul Montastruc*

### Symposium-déjeuner NOVARTIS:

#### Evolution des pratiques dans l'insuffisance cardiaque NOVARTIS

- Modérateur : Vincent RICHARD (Rouen)

- 12h45 Stratégies thérapeutiques dans l'insuffisance cardiaque  
Atul PATHAK (Toulouse)
- 13h05 Quelle place pour le pharmacien dans le prise en charge de l'insuffisance cardiaque -  
Audrey CASTET NICOLAS (Montpellier)
- 13h25 Table ronde

**14h00 - 15h30** *Grand Amphi*

## Thème transversal 2 – Onco-Pharmacologie

▪ Modérateurs : Etienne CHATELUT (Toulouse), Vincent LEVY (Paris)

### Conférences invitées

- 14h00 Thérapies "ciblées" : une appellation judicieuse ? Fabien DESPAS (Toulouse)
- 14h30 La vie des cellules en Société : mécanismes d'action des médicaments d'immunothérapie  
Jean-Jacques FOURNIE (Toulouse)
- 15h00 Quel apport de la modélisation pharmacologique pour l'utilisation et le développement des anticancéreux ? Michel TOD (Lyon)

**15h30 – 16h00**

## Pause café

**16h00 - 17h30** *Grand Amphi*

## Thème transversal 2 – Onco-Pharmacologie

▪ Modérateurs : Véronique LAMARQUE-GARNIER (Paris), Sébastien FAURE (Angers)

### Conférences invitées

- 16h00 Comment évaluer la médecine personnalisée en cancérologie : des études rétrospectives aux essais randomisés - Xavier PAOLETTI (Paris)
- 16h30 L'onco-pharmacoépidémiologie : évaluation des anticancéreux en situation réelle de soins - Annie FOURRIER-REGLAT (Bordeaux)
- 17h00 Nouvelles pistes thérapeutiques ciblant la niche tumorale - Olivier HERAULT (Tours)

**17h30 - 18h30** *Grand Amphi*

## Assemblée Générale de la SFPT et Remise des Prix

**17h30 - 18h30** *Salle du Sénéchal - 17 Rue de Rémusat, 31000 Toulouse*

## Conférence Grand Public : "Médicaments : faut-il en avoir peur ?"

▪ Bernard BEGAUD (Bordeaux)

**18h30 - 19h30** *Mairie de Toulouse, Salle des Illustres - 1 Place du Capitole, 31000 Toulouse*

## Apéritif à la Mairie de Toulouse

**20h00**

## Soirée du congrès à la Chapelle des Carmélites (Cocktail dînatoire - sur inscription)

*1 Rue de Périgord, 31000 Toulouse*

## JEUDI 14 JUIN

**09h00 - 10h00** *Grand Amphi*

## Sujet d'actualité - Levothyrox : variabilité pharmacologique ou variabilité sociétale ?

▪ Modérateurs : Mathieu MOLIMARD (Bordeaux), Stéphane MOULY (Paris)

### Conférences invitées

- 09h00 Variabilité pharmacocinétique – Matthieu ROUSTIT (Grenoble)
- 09h15 Variabilité clinique (au sens pharmaco clinique/PV) – Marie-Christine PERAULT-POCHAT (Poitiers)
- 09h30 Variabilité sociale - Haleh BAGHERI (Toulouse)
- 09h45 Synthèse – Régis BORDET (Lille)

**09h00 - 10h00** *Amphi Paul Montastruc*

## Communications libres

▪ Modérateurs : Gisèle PICKERING (Clermont-Ferrand), Milou DRICI (Nice)

### Communications libres

- 09h00 CO-055 - GLUCOSE Control Safety & Efficacy in type 2 Diabetes, a NETWORK meta-analysis (GLUCOSE DINET) - Guillaume GRENET (Lyon)
- 09h10 CO-056 - Development of a limited sampling strategy for the determination of ruxolitinib exposure in children with steroid-refractory acute graft-versus-host disease - Antoine PETITCOLLIN (Rennes)
- 09h20 CO-057 - Population pharmacokinetic of gentamicin in hemodialysis patients: modeling, simulations and recommendations - Jean-Baptiste WOILLARD (Limoges)
- 09h30 CO-058 - COSMOS study: which psychoactive substances are started in prison? Caroline VICTORRI-VIGNEAU (Nantes)
- 09h40 CO-059 - Piperacillin population pharmacokinetics and optimization in critically ill children with normal and augmented renal clearance - Sihem BENABOUD (Paris)
- 09h50 CO-060 - Evaluation of the effects of etifoxine (100 mg) and lorazepam (2 mg) on alertness and cognitive functions in elderly subjects - Dominique DEPLANQUE (Lille)

**09h00 – 10h00** *Salle Pous*

## Controverse STP-Personnalisation

▪ Modérateurs : Caroline SOLAS (Marseille), Florian LEMAITRE (Rennes)

### Conférences invitées

- 09h00 Suivi thérapeutique des antirétroviraux : POUR - David METSU (Toulouse)
- 09h30 Suivi thérapeutique des antirétroviraux : CONTRE - Patrice MASSIP (Toulouse)

**10h00 – 10h30**

## Pause café

## 10h30 – 12h00 *Grand Amphi*

### Thème transversal 3 : Les dispositifs médicaux

▪ Modérateurs : Béatrice DULY-BOUHANICK (Toulouse), Michel CUCHERAT (Lyon)

#### Conférences invitées

- 10h30 Dépôt d'un dossier de DM : quel circuit en 2018? Du dépôt de dossier jusqu'à l'hôpital – Isabelle ADENOT (Paris)
- 11h00 Le dispositif médical dans le circuit hospitalier – Dominique THIVEAUD (Toulouse)
- 11h30 Les dispositifs médicaux en Neurologie : spécificités de l'évaluation – Béchir JARRAYA (Paris)

## 10h30 – 12h00 *Amphi Paul Montastruc*

### Communications libres- Pharmacovigilance – Addictovigilance

▪ Modérateurs : Maryse LAPEYRE-MESTRE (Toulouse), Reynald LE BOISSELIER (Caen)

#### Conférence invitée

- 10h30 Exposition précoce et vulnérabilité aux substances psychoactives - Laurence LANFUMEY (Paris)

#### Communications libres

- 11h00 CO-049 - ADUC (alcool et drogues à l'université de Caen Normandie): a useful contribution for addictovigilance on student's population - Basile CHRÉTIEN (Caen)
- 11h10 CO-050 - Evolution of analgesics use in France, 2006-2015: results from the DANTE study (Une Décennie d'ANTalgiques En France) - Amélie DAVELUY (Bordeaux)
- 11h20 CO-051 - Increase of complications-related to cocaine use reported to the French Addictovigilance Network – Hélène PEYRIERE (Montpellier)
- 11h30 CO-052 - Pharmacologically controlled drinking in the treatment of alcohol use disorders (AUDs). A network meta-analysis - Florian NAUDET (Rennes)
- 11h40 CO-053 - Misuse of fentanyl patches : results of a 6 years survey of the French Addictovigilance Network - Juliana TOURNEBIZE (Nancy)
- 11h50 CO-054 - French pharmacovigilance of opioid analgesics : results of disproportionality analysis from OPPIDUM (Observation of psychoactive substance consumption) - Joelle MICALLEF (Marseille)

## 12h00 – 12h15 *Grand Amphi*

### Clôture du congrès

## 12h15 – 12h30 *RDC*

### Déjeuner

## 12h45 – 14h45 *Amphi Paul Montastruc*

### Atelier DPC n° 65951800003 (sur inscription) :

**Optimisation de la posologie des médicaments métabolisés par les CYP450, en cas d'interaction médicamenteuse, de polymorphisme génétique ou de cirrhose : Amélioration de la prédiction du risque avec DDI-predictor**

▪ Formateur : Michel TOD (Lyon)

Sylvain GOUTELLE (Lyon), Laurent BOURGUIGNON (Lyon)

## 12h45 – 14h45 *Grand Amphi*

### Atelier DPC n° 65951800002 (sur inscription) :

**Médicaments et grossesse : une nécessaire vigilance**

▪ Formateur : Annie-Pierre JONVILLE-BERA (Tours)

Est-il possible de voir émerger un nouveau tératogène en clinique? Thierry VIAL (Lyon)

Quand et comment prendre en charge une femme exposée à un médicament ? le rôle des CRPV. Séquence interactive de cas pratiques - Isabelle LACROIX (Toulouse), Sophie GAUTIER (Lille)

## 12h45 – 14h45 *Salle Pous*

### Session validant la formation continue en expérimentation animale

▪ Formateur : Bruno GUIARD (Toulouse)

Les biais d'interprétation liés à l'expérimentation animale – Pascal ROULLET (Toulouse)

La douleur : voies, conséquences et traitements - Patrick VERWAERDE (Toulouse)



## Posters affichés Jour 1 : MARDI 12 JUIN

- PS1 - 001 - Safety case reports analysis of progestin-only contraceptives within the French Pharmacovigilance Database - Anne DAUTRICHE (Dijon)
- PS1 - 002 - Differential targeted impact of hydroxyurea and ropeginterferon alfa-2b on tumor clones in Polycythemia Vera - Lydia ROY (Créteil)
- PS1 - 003 - Liposomal amphotericin B pharmacokinetics in a patient with invasive pulmonary aspergillosis treated by extracorporeal membrane oxygenation - Florian LEMAITRE (Rennes)
- PS1 - 004 - Vasorelaxant effects of Eulophia macrobulbon and its main compound in rat mesenteric arteries - Sutthinee WISUTTHATHUM (Phitsanulok)
- PS1 - 005 - Risperidone-induced metabolic dysfunction is attenuated by Curcuma longa extract administration in mice - Olivier PETRAULT (Lille)
- PS1 - 006 - Antipsychotics induced-camptocormia: a case-series - Mélissa YÉLÉHÉ-OKOUMA (Nancy)
- PS1 - 007 - Management of the interaction between lumacaftor/ivacaftor and antifungal prophylaxis in patients with cystic fibrosis - Christelle BOGLIONE-KERRIEN (Rennes)
- PS1 - 008 - Use of opioid substitution therapy: the patient's point of view - Marion LEPELLEY (Grenoble)
- PS1 - 009 - Cirrhotic patients in ICU with gastrointestinal bleeding managed according to recent guidelines display altered brain hemoglobin oxygen's saturation assessed by near infrared spectroscopy. Nicolas WEISS (Paris)
- PS1 - 010 - Unexpected low plasma levels of posaconazole with the gastro-resistant tablet : influence of pre-analytical conditions - Peggy GANDIA (Toulouse)
- PS1 - 011 - Quality control in vigilance database: a tool to guarantee data quality and patient safety in clinical trials - Julie FRESSARD (Lyon)
- PS1 - 012 - Clinical consequences related to defective elimination of clobazam caused by homozygous mutated CYP2C19 allele: a case report - David BOELS (Angers)
- PS1 - 013 - Acute posterior multifocal placoid pigment epitheliopathy after vaccination: Review of the literature and analysis of the French Pharmacovigilance database - Jérémy MANGAVELLE (Saint-Etienne)
- PS1 - 014 - Lack of effects of simvastatin on smoking cessation in humans: A double-blind, randomized, placebo-controlled clinical study - Claire LAFAY-CHEBASSIER (Poitiers)
- PS1 - 015 - Use of cabazitaxel in treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC): patient characteristics, safety and effectiveness in the FUJI cohort - Annie FOURRIER-RÉGLAT (Bordeaux)
- PS1 - 016 - 99m-Tc dimercaptosuccinic acid renal scintigraphy time course allows assessment of interstitial fibrosis development during adenine rich diet in rats. - Guillaume HACHE (Marseille)
- PS1 - 017 - Delayed eruptions with photosensitivity induced by intravenous immunoglobulin infusions - Sandrine COMBRET (Dijon)
- PS1 - 018 - Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d'Ivoire. Jean-Claude YAVO (Abidjan)
- PS1 - 019 - Comparative efficacy of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomized trials - Charles KHOURI (Grenoble)
- PS1 - 020 - A comparative study about drug safety in oncology and frail patients - Malak ABOU TAAM (Reims)
- PS1 - 021 - Free prednisolone pharmacokinetics after oral prednisone administration in patients with inflammatory - immunologic conditions - Olivier MANGIN (Paris)
- PS1 - 022 - Implementation of a national pharmacovigilance system and drug risk management in a French-speaking African country, Côte d'Ivoire : Review and Prospects - Jean-Claude YAVO (Abidjan)
- PS1 - 023 - Role of phosphodiesterases in controlling cGMP compartmentation in cultured vascular smooth muscle cells - Véronique LEBLAIS (Châtenay-Malabry)
- PS1 - 024 - Prevention of invasive Aspergillus fungal infections with the suspension and delayed-release tablet formulations of posaconazole in patients with haematologic malignancies - Noël ZAHR (Paris)
- PS1 - 025 - Evaluation of the effect of benzodiazepines on cognitive status in rats - Youness KADIL (Casablanca)
- PS1 - 026 - Urinary retention: a side effect of Terbinafine? - Marie TRIGUER (Caen)
- PS1 - 027 - Reported vaccination side effects in Franche-Comte over a five-year period - Melanie MOLTENIS (Besancon)
- PS1 - 028 - Thyroiditis and immune check point inhibitors: a national descriptive retrospective non-interventional study based on the French Pharmacovigilance Database - Julie GARON CZMIL (Nancy)
- PS1 - 029 - Use of the French health insurance database for research in the field of mental health: review and perspectives - Alexis REVET (Toulouse)
- PS1 - 030 - Effect of an High Fat Diet and Vitamin D3 supplementation in the aortic valvulopathy EGFrwa2/wa2 murin model - Bérénice COLLEVILLE (ROUEN)
- PS1 - 031 - Audit concerning the medicinal care of elderly patients in a teaching hospital - Juliette DINET (Rouen)
- PS1 - 032 - Impact of a cortical microbleed on cognition and its pharmacological modulation by atorvastatin in female wild-type and transgenic mice - Romain BARUS (Lille)
- PS1 - 033 - Diabetes in a patient with Gaucher disease: adverse drug reaction or disease progression? Louise GABORIAU (Lille)
- PS1 - 034 - Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction - Lamiae GRIMALDI-BENSOUA (Paris)
- PS1 - 035 - Leflunomide for BKvirus: serie of 7 kidney-transplanted children - Manon LAUNAY (Paris)
- PS1 - 036 - Dermatological adverse drug reactions of anticancer drug: international data of pharmacovigilance (VigiBase®) - Mathilde STRUMIA (Toulouse)
- PS1 - 037 - Work interruption in a short-term hospital service: A risk factor for medication error - Juliette DINET (Rouen)
- PS1 - 038 - Topical clobetasol induced necrotizing fasciitis after bullous pemphigoid: case report and review of literature - Louise GABORIAU (Lille)
- PS1 - 039 - Implication of the blood-brain barrier in the physiopathology of hepatic encephalopathy in cirrhosis - Nicolas WEISS (Paris)
- PS1 - 040 - Cyamemazine-induced peripheral edema: a case report - Karine BERQUET (Nantes)
- PS1 - 041 - Adverse drug reactions of statins in a paediatric population: a descriptive analysis of individual case safety reports from VigiBase® Cécile CONTE (Toulouse)
- PS1 - 042 - Misuse of trihexyphenidyl (Artane®) on Réunion island - Romain TORRENTS (Marseille)
- PS1 - 043 - Comparison between voriconazole trough concentration in children and adults - Imed MTAR (Tunis)
- PS1 - 044 - Risk assessment in morphine sulfate off-label use in non-painful opioid dependent patients - Célian BERTIN (Clermont-Ferrand)
- PS1 - 045 - Direct oral anticoagulant-induced hallucination: review of the French Pharmacovigilance Database. Johana BÉNÉ (Lille)
- PS1 - 046 - Confusional state induced by quetiapine - Paul DELAUNAY (Poitiers)
- PS1 - 047 - Differential pharmacokinetic interaction of cyclosporine and tacrolimus with colchicine in renal allograft recipients - laurent BECQUEMONT (Kremlin Bicêtre)
- PS1 - 048 - E-cigarette: a new fashionable, discreet, but risky way to misuse drugs - Basile CHRÉTIEN (Caen)
- PS1 - 049 - Post-marketing surveillance of Arcoxia® (etoricoxib) safety: a 6.5-year follow-up study in France - Marie ZENUT (Clermont-Ferrand)
- PS1 - 050 - Assessment of pre-analytical nonconformities in a laboratory of clinical pharmacology - Issam SALOUAGE (Tunis)
- PS1 - 051 - Does imatinib also slow ALL children patients' growth down? about 2 case reports - Lucie POUCHÉ (Bordeaux)

- PS1 - 052 - ADR involving metoclopramide in children after the indication restriction in 2012: an ongoing issue - Farid KHELOUFI (Marseille)
- PS1 - 053 - Descriptive analysis of the methods of administration of injectable cytotoxic drugs in hospitals - Imane RAHMOUNE (Casablanca)
- PS1 - 054 - Multimodal approach including MR-spectroscopy for the diagnosis of minimal hepatic encephalopathy - Nicolas WEISS (Paris)
- PS1 - 055 - Observational study of the management of patients with chronic pain: OKAPI study - Alexandrine CORRIGER (Clermont-Ferrand)
- PS1 - 057 - Preventability of serious adverse drug reactions in the elderly: analysis of the spontaneous reports to a French pharmacovigilance center over 10 years - Marion LEPELLEY (Grenoble)
- PS1 - 058 - Comparison of drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in French and Vietnamese database (2010-2015) - Khac-Dung NGUYEN (Toulouse)
- PS1 - 059 - Quetiapine-induced immune thrombocytopenia: one case report with two positive rechallenges - Anaïs GAIFFE (Besançon)
- PS1 - 060 - Paliperidone palmitate induced hyponatremia: a fatal case - Anne BERNARD (Nantes)
- PS1 - 061 - The drugs that mostly frequently induce gynecomastia : a case-non case study of a pharmacovigilance database - Benjamin BATTEUX (Amiens)
- PS1 - 062 - Change of clinical trial vigilance software in 6 university hospitals of western France : an experience of data migration - Catherine MOUCHEL (Rennes)
- PS1 - 063 - Acute hepatitis in a regular user of inhaled cocaine: a case report - Emilie BOUQUET (Poitiers)
- PS1 - 064 - Association between venous thromboembolism events and fibrates: a comparative study. - Joachim ALEXANDRE (Caen)
- PS1 - 065 - Terpenes derivatives and risk of seizure: be careful with self-medication! - Basile CHRETIEN (Caen)
- PS1 - 068 - Always check chemical structures in case of reintroduction after a serious adverse reaction: about a case of bronchiolitis obliterans organizing pneumonia with decitabine - Julie LEBRUN (Montpellier)
- PS1 - 069 - Non-cancer drug consumption during the early trajectory of lymphoma survivorship - Fabien DESPAS (Toulouse)
- PS1 - 070 - The course of psychotropic drug use in lymphomas: a pharmaco-epidemiological study in the French Health insurance database - Cécile CONTE (Toulouse)
- PS1 - 071 - Post-marketing surveillance of celecoxib safety: a 12-year follow-up study in France - Marie ZENUT (Clermont-Ferrand)
- PS1 - 072 - Therapeutic drug monitoring as a tool for Assessment of drug interaction between lamotrigine and other antiepileptic drugs - Mouna BEN SASSI (Tunis)
- PS1 - 073 - Exacerbation of a hypocalcemia associated with short term use of omeprazole - Sihem EL-AIDL I (Tunis)
- PS1 - 074 - Is the use of bupivacaine for femoral block by neurostimulation safe? - Issam SALOUAGE (Tunis)
- PS1 - 075 - A young woman presenting a Kikuchi-Fujimoto's disease associated with Drug-Induced Lupus - Galith KALMI (Paris)
- PS1 - 076 - Leukocytoclastic vasculitis induced by lercanidipine - Sihem EL-AIDL I (Tunis)
- PS1 - 077 - Early onset of cognitive impairment associated with valproic acid - Sihem EL-AIDL I (Tunis)
- PS1 - 078 - A high performance liquid chromatography tandem mass spectrometry method for the quantification of eight tyrosine kinase inhibitors in human plasma. - Camille TRON (Rennes)
- PS1 - 079 - Strategy to reduce cholesterol – a review of two approaches: target and fixed-dosage - François GUEYFFIER (Lyon)

## Posters affichés Jour 2 : MERCREDI 13 JUIN

- PS2 - 001 - Hydroxyzine and QT prolongation: three studies in real life - Sophie FEDRIZZI (Caen)
- PS2 - 002 - Pharmacokinetic-Pharmacogenetic exploration of patients presenting unexpected high levels of isavuconazole - Lea DARNAUD (Toulouse)
- PS2 - 003 - Determination of Dolutegravir, Darunavir and Atazanavir unbound fraction in HIV patients by equilibrium dialysis and ultrafiltration using a LC-MS method - David METSU (Toulouse)
- PS2 - 004 - Trends of atropinic (anticholinergic) exposure in the elderly: a ten-year analysis in the French EGB database - Sibylle DE GERMA Y (Toulouse)
- PS2 - 005 - Drug-induced skin ulcer: a disproportionality analysis using data from VigiBase® - Dorothee DURON (Grenoble)
- PS2 - 006 - Relationship Between Adverse Drug Reactions and Unlicensed/Off-label Drug Use in Hospitalized Children (EREMI) - Behrouz KASSAI (Lyon)
- PS2 - 007 - Drug exposure and risk of Acute Liver Failure leading to registration for liver Transplantation (ALFT): results of the SALT-III study in adults in France - Nicholas MOORE (Bordeaux)
- PS2 - 008 - Increase of hospital admission related to cocaine use: results from the national hospital discharge database - Céline EIDEN (Montpellier)
- PS2 - 009 - Blood-brain barrier dysfunction assessed by Protein S-100 beta levels in cirrhotic patients in ICU. Nicolas WEISS (Paris)
- PS2 - 010 - The influenza vaccination coverage among hospital workers: difference in behaviour between medical staff and others health-care workers. Gabriel BERTOLIATTI (Rouen)
- PS2 - 011 - Effectiveness of statins according to cardiovascular risk in the elderly - Julien BEZIN (Bordeaux)
- PS2 - 012 - Complying to the new Jardé law: getting help from an "old" friend. Lessons from the BACLOPHONE trial. Céline LECLERCQ (Lille)
- PS2 - 013 - Misuse of androgenic anabolic steroids by body builders and hepatotoxicity - Aude LAMBERT (Strasbourg)
- PS2 - 014 - Comparison of the adverse effects of direct oral anticoagulants and vitamin K antagonists : from a study conducted at the Regional Pharmacovigilance Center of Reims. Brahim AZZOUZ (Reims)
- PS2 - 015 - Successful rechallenge of rituximab after immediate reaction - AHMED ZAIEM (Tunis)
- PS2 - 016 - Social media screening in pharmacovigilance activities: a new approach - Noémie SCHILLER (Pierre-Bénite)
- PS2 - 017 - Off-label use during pregnancy: analysis of the Néhavi cohort - Marie-Laure LAROCHE (Limoges)
- PS2 - 018 - SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Charles KHOURI (Grenoble)
- PS2 - 019 - Pharmacokinetic adaptations of antibiotic posology: sampling errors in patients with continuous infusion of vancomycin in an university hospital - Sylvain COUDERC (Limoges)
- PS2 - 020 - Adverse Drug Reactions associated with protease inhibitors in children: a comparison of Atazanavir versus Darunavir using data from VigiBase - Joe MIANTEZILA BASILUA (Paris)
- PS2 - 021 - Drug iatrogenic disease and recourse to the adult psychiatric emergencies - Emilie TERRO (Rouen)
- PS2 - 022 - Hormonal therapy-induced meningioma - Aurélie FÉRAL (Amiens)
- PS2 - 023 - Take-home intranasal naloxone: results of one year prescription at an addiction care center - Céline EIDEN (Montpellier)
- PS2 - 024 - Tacrolimus individual dose adjustment using population pharmacokinetics model - Issam SALOUAGE (Tunis)
- PS2 - 025 - Vomiting and constipation associated with tramadol or codeine in VigiBase®: differences explained by pharmacodynamic properties - Jean-Louis MONTASTRUC (Toulouse)

- PS2 - 026 - Safety profiles of BRAF-inhibitors and MEK-inhibitors: analysis of the WHO database of adverse drug reactions, VigiBase® - Marine ROUSSET (Bordeaux)
- PS2 - 027 - Intracellular lithium dosing: which pertinence? - Caroline VICTORRI-VIGNEAU (Nantes)
- PS2 - 028 - Validation of a simple and rapid HPLC-DAD method for the routine therapeutic drug monitoring of ceftolozane in critically ill patients - Youssef BENNIS (Amiens)
- PS2 - 029 - Level of pharmacological knowledge of street drug sellers - Mamadou KAMAGATE (Bouaké)
- PS2 - 030 - Curcuma longa extract inhibits risperidone induced metabolic abnormalities in mice - Olivier PETRAULT (Lille)
- PS2 - 031 - Development of a document to aid sites to report adverse events in clinical trials - Anaïs EL HACHEMI (Pierre-Bénite)
- PS2 - 032 - Current prescription practices of antipsychotics in the treatment of psychotic disorders in the psychiatric hospital of Nancy, France - Juliana TOURNEBIZE (Nancy)
- PS2 - 033 - Dietary supplement consumption leading to hospitalisations: case series - Louise GABORIAU (Lille)
- PS2 - 034 - Real-life treatment and survival in metastatic colorectal cancer elderly patients: a French population-based study - Amandine GOUVERNEUR (Bordeaux)
- PS2 - 035 - Drug-induced Trigeminal Autonomic Cephalgia (TAC) in the French Pharmacovigilance database - Marie-Noëlle BEYENS (Saint Etienne)
- PS2 - 036 - Psychoactive Substance consumption among teenagers: Results from Addictovigilance monitoring - Liselotte POCHARD (Marseille)
- PS2 - 037 - Evaluation of direct oral anticoagulants (DOAC) prescriptions at St Etienne University Hospital Center - Pierre BRUNEL (Saint-Etienne)
- PS2 - 038 - Drug-induced Pisa syndrome: a literature review - Céline LENGELLÉ (Tours)
- PS2 - 039 - Dose-dependent kinetic analysis of metabolite changes after ethanol intoxication in rat prefrontal cortex using in vivo magnetic resonance spectroscopy - Louise CARTON (Lille)
- PS2 - 040 - Risk of Vaccine-Induced Immune Thrombocytopenia in Children. A nationwide case cross-over study in France - Agnès SOMMET (Toulouse)
- PS2 - 041 - Vicks® VapoRub: use, misuse and risks - Johana BÉNÉ (Lille)
- PS2 - 042 - Self medication by NPS in a patient with adult ADHD - Olivier MENARD (Lille)
- PS2 - 043 - Adverse reactions associated with hepatitis C treatment - AHMED ZAIEM (Tunis)
- PS2 - 044 - Drug-induced acute liver injury (ALI) in the French claims database: description of cases - Nicholas MOORE (Bordeaux)
- PS2 - 045 - Contribution of NO and Impact of aging in flow mediated dilatation in healthy patients: meta-analysis and meta-regression - Zoubir DJERADA (Rouen/reims)
- PS2 - 046 - Phenobarbital induced DRESS syndrome: an atypical presentation - AHMED ZAIEM (Tunis)
- PS2 - 047 - Leuprorelin and ulceration at the site of injection: about three serious cases - Julie LEBRUN (Montpellier)
- PS2 - 048 - Development and validation of a specific, high-range, high-throughput enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab - Antoine PETITCOLLIN (Rennes)
- PS2 - 049 - Hepatic cytolysis and acute hepatic failure induced by a triple drug interaction (ponatinib, voriconazole, azithromycine): a case report - Delphine BOURNEAU-MARTIN (Angers)
- PS2 - 050 - Effect of CYP3A5, CYP3A4 and ABCB1 polymorphisms on tacrolimus exposure in renal transplantation patients - Marwa AJMI (Sousse)
- PS2 - 051 - Should imatinib regimen be adapted and monitored in CML children patients? Experience initiated from a case report - Stéphane BOUCHET (Bordeaux)
- PS2 - 052 - Adverse drug reactions related to drug-drug interactions: lower severity level of drug drug interactions and pharmacodynamic interactions are oversighted - Farid KHELOUFI (Marseille)
- PS2 - 053 - Implication of the antidepressants in sexual dysfunctions in patients with major depressive disorder - Caroline VICTORRI-VIGNEAU (Nantes)
- PS2 - 054 - Drugs, Adverse Drug Reactions and Pharmacovigilance in the Adventures of Tintin - Jean-Louis MONTASTRUC (Toulouse)
- PS2 - 055 - Immunoglobulins: Benefits and risks from the patient's point of view - Bruno REVOL (Grenoble)
- PS2 - 056 - Impact of the implementation of zolpidem secured prescription: the ZORRO project - Marie GERARDIN (Nantes)
- PS2 - 057 - Treatment of allogeneic hematopoietic stem cell transplant recipients by posaconazole tablets: is therapeutic drug monitoring still useful? Elodie GAUTIER-VEYRET (Grenoble)
- PS2 - 058 - Cefazolin and piperacillin/tazobactam stability related to environmental factors in drug infusion bag: first step required before therapeutic drug monitoring. - David METSU (Toulouse)
- PS2 - 059 - Biotin may interfere with laboratory tests - Julien MAHE (Nantes)
- PS2 - 060 - Coronary artery vasospasm with iron sucrose: a case report - Sylvie PICARD (Rennes)
- PS2 - 061 - Adverse Drug Reactions of blinatumomab: a study in the French Pharmacovigilance Database - SYLVINE PINEL (Paris)
- PS2 - 062 - A smartphone application to support prescription - Louis LÉTINIER (Bordeaux)
- PS2 - 063 - Benzylthiouracile- Induced ANCA-Associated Vasculitis: A Case report - Fatima BENSIRADJ (Rouen)
- PS2 - 064 - Inpatients for cocaine detoxification at Montpellier University Hospital - Hélène PEYRIERE (Montpellier)
- PS2 - 065 - A rarely described use of neostigmine in a case of acute anticholinergic poisoning - Romain TORRENTS (Marseille)
- PS2 - 066 - leucocytoclastic vasculitis after taking rosuvastatin : a new case - Claire LAFAY-CHEBASSIER (Poitiers)
- PS2 - 067 - Multivisceral impairment in a DRESS Syndrome - ons CHARFI (Tunis)
- PS2 - 068 - A one year follow up about two cases of optic neuritis under golimumab therapy (anti-TNFa) for ankylosing spondylitis revealing demyelinating disorders and multiple sclerosis - Christophe MAUCORPS (Caen)
- PS2 - 069 - Melatonin: from pharmacokinetics to a better clinical use in Autism Spectrum Disorder - Sébastien LALANNE (Rennes)
- PS2 - 070 - Involving children and young persons in clinical research through the forum of a European young person's advisory group: Needs & Challenges. - Segolene GAILLARD (Lyon)
- PS2 - 071 - Impact of the pharmacist on the potentially inappropriate medication prescriptions in older patients in ambulatory care. Marie-Laure LAROCHE (Limoges)
- PS2 - 072 - Efficacy of fosfomycin trometamol for the prevention of recurrent urinary tract infections in 86 patients - Sophie ISMAEL (Paris)
- PS2 - 073 - Captopril induced acute pancreatitis associated to angioedema - Riadh DAGHFOUS (Tunis)
- PS2 - 074 - Cutaneous reactions due to allopurinol: a report of 25 cases - Imane RAHMOUNE (Casablanca)
- PS2 - 075 - Skin tests in hypersensitivity reactions associated with iodinated contrast media - El-Aidli SIHEM (Tunis)
- PS2 - 076 - DRESS syndrome in an 8-year-old child associated with amoxicillin - Sihem EL-AIDLII (Tunis)
- PS2 - 077 - Recurrent swelling of the lower lip associated with local anesthetics - Sihem EL-AIDLII (Tunis)
- PS2 - 078 - Vancomycin-induced eruption in the setting of oral use is not that absurd: a case report and possible explanations - Farid KHELOUFI (Marseille).

## Lieu du congrès

**Faculté de Médecine**  
37 allée Jules Guesde  
31000 Toulouse

## Dates du congrès

**Mardi 12 au Jeudi 14 juin 2018**

## Horaires du congrès

**Mardi 12 juin 2018 : 12h00 – 18h00**  
(accueil à partir de 10h00)

**Mercredi 13 juin 2018 : 8h30 – 18h30**  
(accueil à partir de 8h00)

**Jeudi 14 juin 2018 : 9h00 – 12h15**  
(accueil à partir de 8h30)



## Restauration

Les pauses et déjeuners sont inclus dans le tarif d'inscription, et auront lieu au RDC du mardi au jeudi.

## Soirée du congrès

La soirée se tiendra le **mercredi 13 juin à partir de 20h00 - Chapelle des Carmélites**  
1 rue du Périgord, 31000 Toulouse.

- **Accès à pieds depuis la Faculté** (environ 20 minutes) : remonter la rue Ozenne, puis la rue Alsace Lorraine jusqu'à la rue du Salé. A la rue du Salé, prendre à droite, traverser le rue de Rémusat et continuer sur la rue du Périgord.
- **En métro** : remonter la rue Ozenne à pieds puis prendre la ligne B à la station CARMES en direction de Borderouge. Descendre à la station Jeanne D'Arc puis traverser le Boulevard de Strasbourg. Continuer sur la rue Alsace Lorraine, puis sur la rue de Rémusat. Puis prendre à droite rue du Périgord.

**Participation sur inscription – les réservations ne pourront pas se faire sur place.**

## Badge

Votre badge, attestation de présence et sacoches contenant les documents du congrès vous seront remis à votre arrivée à l'accueil.

Pour des raisons de sécurité, le port du badge est obligatoire pendant toute la durée du congrès.

## Orateurs

Les orateurs sont invités à se présenter en salle de conférence munis d'une clé USB afin de déposer leur présentation PPT au technicien présent en salle, **au moins 2 heures** avant le début de la session.

# NOTES



SFPT 2018

# REMERCIEMENTS

La SFPT remercie ses partenaires pour l'intérêt et le soutien qu'ils ont apportés à ce congrès.



# Rendez-vous pour l'édition 2019 !

Du 12 au 14 juin 2019 à Lyon - Faculté de Médecine LAËNNEC

